Skip to main content

news

 

Skadden, Arps, Slate, Meagher & Flom has advised Japan's Otsuka Pharmaceutical on its $1.1 billion agreement to acquire Boston-based Jnana Therapeutics, which was represented by Latham & Watkins.

Large Japanese drugmakers have been on an overseas acquisition spree of late as they look to replenish their drug portfolios, with Otsuka joining the likes of Ono Pharma, Takeda Pharmaceutical, and Astellas Pharma.

According to Reuters, Otsuka will pay $800 million to Jnana shareholders along with up to $325 million in development and regulatory milestones. It added that Jnana is a clinical-stage biotechnology company with drug candidates for rare diseases and immune disorders.

The Skadden team was led by partners Mitsuhiro Kamiya and Mike Mies, and included partners Ken Kumayama, Joe Yaffe, David Schwartz, Nate Giesselman, Michael Leiter, Brian Egan, Avia Dunn, Nesa Amamoo, and Peter Luneau.

The Latham team was led by partners Leah Sauter and Peter Handrinos, with support from partners Matthew Conway, Katharine Moir, Aaron Gardner, Heather Deixler, Elizabeth Richards, and Patrick English.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.

Wadia Ghandy, CAM guide StanChart’s $490 mln sale of personal loan business

by Nimitt Dixit |

Wadia Ghandy has guided Kotak Mahindra on its acquisition of Standard Chartered Bank’s personal loan business in India for $490 million, with Cyril Amarchand Mangaldas advising Standard Chartered.

AZB, S&R act on $645 mln Afcons IPO

by Nimitt Dixit |

AZB & Partners is advising Afcons, one of India’s largest international infrastructure construction companies, on its upcoming initial public offering worth $645 million. S&R Associates is acting for the bookrunning lead managers.